Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials

European Journal of Pharmacology

Volumn 763, Issue , 2015, Pages 48-63

  Kühnast, Susan ^a,b   Fiocco, Marta ^b,c   Van Der Hoorn, José W A ^a,b   Princen, Hans M G ^a   Jukema, J Wouter ^b  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

3Leiden.CETP mice; ABCA1 degradation inhibitors; APOE; Apolipoprotein A I inducer; Apolipoprotein A I Milano; Apolipoprotein A I mimetic; Atherosclerosis; Cardiovascular disease; CETP inhibition; Clinical outcome; Clinical trials; Delipidated HDL; Fibrates; Glitazones; Hamster; HDL cholesterol; LCAT; LDL cholesterol; Mouse; Myocardial infarction; Niacin; Non HDL cholesterol; PPAR agonists; Rabbit; Reconstituted HDL; SR BI inhibitor

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 INDUCER; ATP BINDING CASSETTE A1 DEGRADATION INHIBITOR; CARDIOVASCULAR AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; FIBRIC ACID DERIVATIVE; GLITAZAR DERIVATIVE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEPTIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; RECEPTOR BLOCKING AGENT; SCAVENGER RECEPTOR BI INHIBITOR; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK MANAGEMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM; PRECLINICAL STUDY;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG EVALUATION, PRECLINICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941744434     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.03.089     Document Type: Review

References (106)

1. S. Ameli, A. Hultgardh-Nilsson, B. Cercek, P.K. Shah, J.S. Forrester, H. Ageland, and J. Nilsson Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 90 1994 1935 1941
2. R. Arakawa, M. Tsujita, N. Iwamoto, C. Ito-Ohsumi, R. Lu, C.A. Wu, K. Shimizu, T. Aotsuka, H. Kanazawa, S. Abe-Dohmae, and S. Yokoyama Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis J. Lipid Res. 50 2009 2299 2305
3. J.J. Badimon, L. Badimon, and V. Fuster Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J. Clin. Invest. 85 1990 1234 1241
4. C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, R. Collins, and Cholesterol Treatment Trialists' Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
5. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes, and Cholesterol Treatment Trialists' Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
6. J.W. Balder, B. Staels, and J.A. Kuivenhoven Pharmacological interventions in human HDL metabolism Curr. Opin. Lipidol. 24 2013 500 509
7. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R. Tall, B. Brewer, and The ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122
8. P.J. Barter, and K.A. Rye Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk J. Lipid Res. 53 2012 1755 1766
9. Bezafibrate Infarction Prevention (BIP) Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study Circulation 102 2000 21 27
10. S. Bijland, E.J. Pieterman, A.C. Maas, J.W. van der Hoorn, M.J. van Erk, J.B. van Klinken, L.M. Havekes, K.W. van Dijk, H.M. Princen, and P.C. Rensen Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE∗3-Leiden.CETP mice J. Biol. Chem. 285 2010 25168 25175
11. R. Bitzur, H. Cohen, Y. Kamari, and D. Harats Intolerance to statins: mechanisms and management Diabetes Care 36 Suppl 2 2013 S325 S330
12. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, W. Weintraub, and The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 365 2011 2255 2267
13. S.M. Boekholdt, B.J. Arsenault, G.K. Hovingh, S. Mora, T.R. Pedersen, J.C. Larosa, K.M. Welch, P. Amarenco, D.A. Demicco, A.M. Tonkin, D.R. Sullivan, A. Kirby, H.M. Colhoun, G.A. Hitman, D.J. Betteridge, P.N. Durrington, M.B. Clearfield, J.R. Downs, A.M. Gotto Jr., P.M. Ridker, and J.J. Kastelein Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis Circulation 128 2013 1504 1512
14. M.L. Bots, F.L. Visseren, G.W. Evans, W.A. Riley, J.H. Revkin, C.H. Tegeler, C.L. Shear, W.T. Duggan, R.M. Vicari, D.E. Grobbee, J.J. Kastelein, and The RADIANCE 2 Investigators Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160
15. M.L. Brown, A. Inazu, C.B. Hesler, L.B. Agellon, C. Mann, M.E. Whitlock, Y.L. Marcel, R.W. Milne, J. Koizumi, H. Mabuchi, and et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins Nature 342 1989 448 451
16. L.M. Buja, T. Kita, J.L. Goldstein, Y. Watanabe, and M.S. Brown Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia Arteriosclerosis 3 1983 87 101
17. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto, M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf, J. Zafarino, Y. Mitchel, P. Barter, and The DEFINE Investigators Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 363 2010 2406 2415
18. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J. Intern. Med. 258 2005 94 114
19. W.P. Castelli, J.T. Doyle, T. Gordon, C.G. Hames, M.C. Hjortland, S.B. Hulley, A. Kagan, and W.J. Zukel HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study Circulation 55 1977 767 772
20. M.J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J. 31 2010 149 164
21. Z. Chen, S.P. Wang, M.L. Krsmanovic, J. Castro-Perez, K. Gagen, V. Mendoza, R. Rosa, V. Shah, T. He, S.J. Stout, N.S. Geoghagen, S.H. Lee, D.G. McLaren, L. Wang, T.P. Roddy, A.S. Plump, B.K. Hubbard, C.J. Sinz, and D.G. Johns Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters Metabolism 61 2012 470 481
22. G. Chiesa Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks Circ. Res. 90 2002 974 980
23. R. Corti, J. Osende, R. Hutter, J.F. Viles-Gonzalez, U. Zafar, C. Valdivieso, G. Mizsei, J.T. Fallon, V. Fuster, and J.J. Badimon Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI Atherosclerosis 190 2007 106 113
24. M.H. Davidson, K.C. Maki, T.A. Pearson, R.C. Pasternak, P.C. Deedwania, J.M. McKenney, G.C. Fonarow, D.J. Maron, B.J. Ansell, L.T. Clark, and C.M. Ballantyne Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations Am. J. Cardiol. 96 2005 556 563
25. M.H. Davidson, R.S. Rosenson, K.C. Maki, S.J. Nicholls, C.M. Ballantyne, T. Mazzone, D.M. Carlson, L.A. Williams, M.T. Kelly, H.S. Camp, A. Lele, and J.C. Stolzenbach Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST) Arterioscler. Thromb. Vasc. Biol. 34 2014 1298 1306
26. W. de Haan, J. de Vries-van der Weij, J.W. van der Hoorn, T. Gautier, C.C. van der Hoogt, M. Westerterp, J.A. Romijn, J.W. Jukema, L.M. Havekes, H.M. Princen, and P.C. Rensen Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin Circulation 117 2008 2515 2522
27. W. de Haan, C.C. van der Hoogt, M. Westerterp, M. Hoekstra, G.M. Dallinga-Thie, H.M. Princen, J.A. Romijn, J.W. Jukema, L.M. Havekes, and P.C. Rensen Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE∗3-Leiden.CETP mice Atherosclerosis 197 2008 57 63
28. P. de Knijff, A.M. van den Maagdenberg, A.F. Stalenhoef, J.A. Leuven, P.N. Demacker, L.P. Kuyt, R.R. Frants, and L.M. Havekes Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree J. Clin. Invest. 88 1991 643 655
29. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control. Clin. Trials 7 1986 177 188
30. E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, A. Thompson, A.M. Wood, S. Lewington, N. Sattar, C.J. Packard, R. Collins, S.G. Thompson, J. Danesh, and Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease J. Am. Med. Assoc. 302 2009 1993 2000
31. Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
32. J.A. Dormandy, B. Charbonnel, D.J.A. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefèbvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Korányi, M. Laakso, M. Mokáň, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Škrha, U. Smith, J. Tatoň, and The PROactive Investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
33. E. Ehrenborg, and J. Skogsberg Peroxisome proliferator-activated receptor delta and cardiovascular disease Atherosclerosis 231 2013 95 106
34. G. Franceschini, C.R. Sirtori, A. Capurso 2nd, K.H. Weisgraber, and R.W. Mahley A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family J. Clin. Invest. 66 1980 892 900
35. G. Franceschini, G. Vecchio, G. Gianfranceschi, D. Magani, and C.R. Sirtori Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant J. Biol. Chem. 260 1985 16321 16325
36. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, and et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N. Engl. J. Med. 317 1987 1237 1245
37. M.H. Frick, O.P. Heinonen, J.K. Huttunen, P. Koskinen, M. Manttari, and V. Manninen Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population Ann. Med. 25 1993 41 45
38. Q. Gaofu, L. Jun, Z. Xiuyun, L. Wentao, W. Jie, and L. Jingjing Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model Life Sci. 77 2005 2690 2702
39. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse 3rd, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr., W.C. Cushman, D.G. Simons-Morton, R.P. Byington, and The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N. Engl. J. Med. 362 2010 1563 1574
40. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, J.D. Knoke, D.R. Jacobs, S. Bangdiwala, and H.A. Tyroler High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
41. C.L. Haase, A. Tybjaerg-Hansen, A.A. Qayyum, J. Schou, B.G. Nordestgaard, and R. Frikke-Schmidt LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals J. Clin. Endocrinol. Metab. 97 2012 E248 E256
42. M. Hanefeld, S. Fischer, H. Schmechel, G. Rothe, J. Schulze, H. Dude, U. Schwanebeck, and U. Julius Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM Diabetes Care 14 1991 308 317
43. E.J. Hennessy, and K.J. Moore Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline J. Cardiovasc. Pharmacol. 62 2013 247 254
44. Z. Huang, A. Inazu, A. Nohara, T. Higashikata, and H. Mabuchi Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia Clin. Sci. 103 2002 587 594
45. B. Ibanez, C. Giannarelli, G. Cimmino, C.G. Santos-Gallego, M. Alique, A. Pinero, G. Vilahur, V. Fuster, L. Badimon, and J.J. Badimon Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type) Atherosclerosis 220 2012 72 77
46. B. Ibanez, G. Vilahur, G. Cimmino, W.S. Speidl, A. Pinero, B.G. Choi, M.U. Zafar, C.G. Santos-Gallego, B. Krause, L. Badimon, V. Fuster, and J.J. Badimon Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis J. Am. Coll. Cardiol. 51 2008 1104 1109
47. A. Iwata, S. Miura, B. Zhang, S. Imaizumi, Y. Uehara, M. Shiomi, and K. Saku Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits Atherosclerosis 218 2011 300 307
48. R. Jahagirdar, H. Zhang, S. Azhar, J. Tobin, S. Attwell, R. Yu, J. Wu, K.G. McLure, H.C. Hansen, G.S. Wagner, P.R. Young, R.A. Srivastava, N.C. Wong, and J. Johansson A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice Atherosclerosis 236 2014 91 100
49. K.A.M. Jandeleit-Dahm, A. Calkin, C. Tikellis, and M. Thomas Direct antiatherosclerotic effects of PPAR agonists Curr. Opin. Lipidol. 20 2009 24 29
50. L. Jun, L. Jie, Y. Dongping, Y. Xin, L. Taiming, C. Rongyue, W. Jie, and L. Jingjing Effects of nasal immunization of multi-target preventive vaccines on atherosclerosis Vaccine 30 2012 1029 1037
51. V.S. Kamanna, S.H. Ganji, and M.L. Kashyap Recent advances in niacin and lipid metabolism Curr. Opin. Lipidol. 24 2013 239 245
52. J.J. Kastelein, S.I. van Leuven, L. Burgess, G.W. Evans, J.A. Kuivenhoven, P.J. Barter, J.H. Revkin, D.E. Grobbee, W.A. Riley, C.L. Shear, W.T. Duggan, M.L. Bots, and The RADIANCE 1 Investigators Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N. Engl. J. Med. 356 2007 1620 1630
53. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y.A. Kesaniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, M. Laakso, and The Field Study Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
54. B.A. Kingwell, M.J. Chapman, A. Kontush, and N.E. Miller HDL-targeted therapies: progress, failures and future Nat. Rev. Drug Discov. 13 2014 445 464
55. T. Kooistra, L. Verschuren, J. de Vries-van der Weij, W. Koenig, K. Toet, H.M. Princen, and R. Kleemann Fenofibrate reduces atherogenesis in ApoE∗3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol Arterioscler. Thromb. Vasc. Biol. 26 2006 2322 2330
56. S. Kuhnast, M.C. Louwe, M.M. Heemskerk, E.J. Pieterman, J.B. van Klinken, S.A. van den Berg, J.W. Smit, L.M. Havekes, P.C. Rensen, J.W. van der Hoorn, H.M. Princen, and J.W. Jukema Niacin reduces atherosclerosis development in APOE∗3Leiden.CETP mice mainly by reducing nonHDL-cholesterol PLoS One 8 2013 e66467
57. S. Kuhnast, J.W. van der Hoorn, E.J. Pieterman, A.M. van den Hoek, W.J. Sasiela, V. Gusarova, A. Peyman, H.L. Schafer, U. Schwahn, J.W. Jukema, and H.M. Princen Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin J. Lipid Res. 55 2014 2103 2112
58. S. Kuhnast, J.W. van der Hoorn, A.M. van den Hoek, L.M. Havekes, G. Liau, J.W. Jukema, and H.M. Princen Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE∗3Leiden.CETP transgenic mice with or without treatment with atorvastatin J. Hypertens. 30 2012 107 116
59. S. Kuhnast, S.J. van der Tuin, J.W. van der Hoorn, J.B. van Klinken, B. Simic, E. Pieterman, L.M. Havekes, U. Landmesser, T.F. Luscher, K. Willems van Dijk, P.C. Rensen, J.W. Jukema, and H.M. Princen Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin Eur. Heart J. 36 2015 39 48
60. F. Lalloyer, and B. Staels Fibrates, glitazones, and peroxisome proliferator-activated receptors Arterioscler. Thromb. Vasc. Biol. 30 2010 894 899
61. M.J. Landray, R. Haynes, J.C. Hopewell, S. Parish, T. Aung, J. Tomson, K. Wallendszus, M. Craig, L. Jiang, R. Collins, J. Armitage, and The HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients N. Engl. J. Med. 371 2014 203 212
62. S. Lewington, G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, J. Halsey, N. Qizilbash, R. Peto, R. Collins, and Prospective Studies Collaboration Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
63. P. Libby The forgotten majority: unfinished business in cardiovascular risk reduction J. Am. Coll. Cardiol. 46 2005 1225 1228
64. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, and D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
65. A.M. Lincoff, J.C. Tardif, G.G. Schwartz, S.J. Nicholls, L. Ryden, B. Neal, K. Malmberg, H. Wedel, J.B. Buse, R.R. Henry, A. Weichert, R. Cannata, A. Svensson, D. Volz, D.E. Grobbee, and The AleCardio Investigators Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial J. Am. Med. Assoc. 311 2014 1515 1525
66. D. Mao, G. Kai, Q. Gaofu, Z. Zheng, Z. Li, W. Jie, L. Jingjing, and C. Rongyue Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis Vaccine 24 2006 4942 4950
67. D. Masson, M. Koseki, M. Ishibashi, C.J. Larson, S.G. Miller, B.D. King, and A.R. Tall Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor Arterioscler. Thromb. Vasc. Biol. 29 2009 2054 2060
68. T. Meade, R. Zuhrie, C. Cook, J. Cooper, and MRC General Practice Research Framework Bezafibrate in men with lower extremity arterial disease: randomised controlled trial BMJ 325 2002 1139
69. H. Mezdour, T. Yamamura, S. Nomura, and A. Yamamoto Exogenous supply of artificial lipoproteins does not decrease susceptibility to atherosclerosis in cholesterol-fed rabbits Atherosclerosis 113 1995 237 246
70. N.E. Miller, D.S. Thelle, O.H. Forde, and O.D. Mjos The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study Lancet 1 1977 965 968
71. A. Miyazaki, S. Sakuma, W. Morikawa, T. Takiue, F. Miake, T. Terano, M. Sakai, H. Hakamata, Y. Sakamoto, M. Natio, and et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits Arterioscler. Thromb. Vasc. Biol. 15 1995 1882 1888
72. L.A. Morehouse, E.D. Sugarman, P.A. Bourassa, T.M. Sand, F. Zimetti, F. Gao, G.H. Rothblat, and A.J. Milici Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J. Lipid Res. 48 2007 1263 1272
73. S.J. Nicholls, B. Cutri, S.G. Worthley, P. Kee, K.A. Rye, S. Bao, and P.J. Barter Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits Arterioscler. Thromb. Vasc. Biol. 25 2005 2416 2421
74. S.J. Nicholls, E.M. Tuzcu, I. Sipahi, P. Schoenhagen, T. Crowe, S. Kapadia, and S.E. Nissen Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano J. Am. Coll. Cardiol. 47 2006 992 997
75. S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan, W. Ruzyllo, W.B. Bachinsky, G.P. Lasala, E.M. Tuzcu, I., and The ILLUSTRATE Investigators Effect of torcetrapib on the progression of coronary atherosclerosis N. Engl. J. Med. 356 2007 1304 1316
76. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, M. Yasin, G.M. Eaton, M.A. Lauer, W.S. Sheldon, C.L. Grines, S. Halpern, T. Crowe, J.C. Blankenship, and R. Kerensky Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial J. Am. Med. Assoc. 290 2003 2292 2300
77. H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203 207
78. C. Parolini, M. Marchesi, P. Lorenzon, M. Castano, E. Balconi, L. Miragoli, L. Chaabane, A. Morisetti, V. Lorusso, B.J. Martin, C.L. Bisgaier, B. Krause, R.S. Newton, C.R. Sirtori, and G. Chiesa Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging J. Am. Coll. Cardiol. 51 2008 1098 1103
79. M.R. Parwaresch, H. Haacke, and C. Mader Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds Atherosclerosis 31 1978 395 401
80. F.H. Rached, M.J. Chapman, and A. Kontush An overview of the new frontiers in the treatment of atherogenic dyslipidemias Clin. Pharmacol. Ther. 96 2014 57 63
81. A.T. Remaley, G.D. Norata, and A.L. Catapano Novel concepts in HDL pharmacology Cardiovasc. Res. 103 2014 423 428
82. P.M. Ridker LDL cholesterol: controversies and future therapeutic directions Lancet 384 2014 607 617
83. C.W. Rittershaus, D.P. Miller, L.J. Thomas, M.D. Picard, C.M. Honan, C.D. Emmett, C.L. Pettey, H. Adari, R.A. Hammond, D.T. Beattie, A.D. Callow, H.C. Marsh, and U.S. Ryan Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler. Thromb. Vasc. Biol. 20 2000 2106 2112
84. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.J. Schaefer, G. Schectman, T.J. Wilt, J. Wittes, and The VA-HIT Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N. Engl. J. Med. 341 1999 410 418
85. J. Sakamoto, H. Kimura, S. Moriyama, H. Odaka, Y. Momose, Y. Sugiyama, and H. Sawada Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochem. Biophys. Res. Commun. 278 2000 704 711
86. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, J. Brumm, B.R. Chaitman, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, H. Mundl, S.J. Nicholls, P.K. Shah, J.C. Tardif, R.S. Wright, and The dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 367 2012 2089 2099
87. J.A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A.M. Dart Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque Circ. Res. 103 2008 1084 1091
88. C.R. Sirtori, L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, J. Johansson, M. Salvetti, C. Monteduro, R. Zulli, M.L. Muiesan, and E. Agabiti-Rosei Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study Circulation 103 2001 1949 1954
89. M.R. Soma, E. Donetti, C. Parolini, C.R. Sirtori, R. Fumagalli, and G. Franceschini Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits Circ. Res. 76 1995 405 411
90. R.A. Srivastava Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters Atherosclerosis 214 2011 86 93
91. M. Sugano Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits J. Biol. Chem. 273 1998 5033 5036
92. M. Tani, R. Matera, K.V. Horvath, T.S. Hasan, E.J. Schaefer, and B.F. Asztalos The influence of apoE-deficiency and LDL-receptor-deficiency on the HDL subpopulation profile in mice and in humans Atherosclerosis 233 2014 39 44
93. J.C. Tardif, C.M. Ballantyne, P. Barter, J.L. Dasseux, Z.A. Fayad, M.C. Guertin, J.J. Kastelein, C. Keyserling, H. Klepp, W. Koenig, L. L'Allier P, J. Lesperance, T.F. Luscher, J.F. Paolini, A. Tawakol, D.D. Waters, and The CHI-SQUARE Investigators Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial Eur. Heart J. 35 2014 3277 3286
94. J.C. Tardif, J. Gregoire, P.L. L'Allier, R. Ibrahim, J. Lesperance, T.M. Heinonen, S. Kouz, C. Berry, R. Basser, M.A. Lavoie, M.C. Guertin, J. Rodes-Cabau, and The ERASE Investigators Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial J. Am. Med. Assoc. 297 2007 1675 1682
95. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease J. Am. Med. Assoc. 231 1975 360 381
96. J.C. van Capelleveen, H.B. Brewer, J.J. Kastelein, and G.K. Hovingh Novel therapies focused on the high-density lipoprotein particle Circ. Res. 114 2014 193 204
97. C.C. van der Hoogt, W. de Haan, M. Westerterp, M. Hoekstra, G.M. Dallinga-Thie, J.A. Romijn, H.M. Princen, J.W. Jukema, L.M. Havekes, and P.C. Rensen Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression J. Lipid Res. 48 2007 1763 1771
98. J.W. van der Hoorn, W. de Haan, J.F. Berbee, L.M. Havekes, J.W. Jukema, P.C. Rensen, and H.M. Princen Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice Arterioscler. Thromb. Vasc. Biol. 28 2008 2016 2022
99. J.W. van der Hoorn, J.W. Jukema, L.M. Havekes, E. Lundholm, G. Camejo, P.C. Rensen, and H.M. Princen The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE∗3Leiden.CETP transgenic mice Br. J. Pharmacol. 156 2009 1067 1075
100. B.J. Van Lenten, A.C. Wagner, M. Navab, G.M. Anantharamaiah, S. Hama, S.T. Reddy, and A.M. Fogelman Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits J. Lipid Res. 48 2007 2344 2353
101. B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M.K. Jensen, G. Hindy, H. Hólm, E.L. Ding, T. Johnson, H. Schunkert, N.J. Samani, R. Clarke, J.C. Hopewell, J.F. Thompson, M. Li, G. Thorleifsson, C. Newton-Cheh, K. Musunuru, J.P. Pirruccello, D. Saleheen, L. Chen, A.F.R. Stewart, A. Schillert, U. Thorsteinsdottir, G. Thorgeirsson, S. Anand, J.C. Engert, T. Morgan, J. Spertus, M. Stoll, K. Berger, N. Martinelli, D. Girelli, P.P. McKeown, C.C. Patterson, S.E. Epstein, J. Devaney, M.-S. Burnett, V. Mooser, S. Ripatti, I. Surakka, M.S. Nieminen, J. Sinisalo, M.-L. Lokki, M. Perola, A. Havulinna, U. de Faire, B. Gigante, E. Ingelsson, T. Zeller, P. Wild, P.I.W. de Bakker, O.H. Klungel, A.-H. Maitland-van der Zee, B.J.M. Peters, A. de Boer, D.E. Grobbee, P.W. Kamphuisen, V.H.M. Deneer, C.C. Elbers, N.C. Onland-Moret, M.H. Hofker, C. Wijmenga, W.M.M. Verschuren, J.M.A. Boer, Y.T. van der Schouw, A. Rasheed, P. Frossard, S. Demissie, C. Willer, R. Do, J.M. Ordovas, G.R. Abecasis, M. Boehnke, K.L. Mohlke, M.J. Daly, C. Guiducci, N.P. Burtt, A. Surti, E. Gonzalez, S. Purcell, S. Gabriel, J. Marrugat, J. Peden, J. Erdmann, P. Diemert, C. Willenborg, I.R. König, M. Fischer, C. Hengstenberg, A. Ziegler, I. Buysschaert, D. Lambrechts, F. Van de Werf, K.A. Fox, N.E. El Mokhtari, D. Rubin, J. Schrezenmeir, S. Schreiber, A. Schäfer, J. Danesh, S. Blankenberg, R. Roberts, R. McPherson, H. Watkins, A.S. Hall, K. Overvad, E. Rimm, E. Boerwinkle, A. Tybjaerg-Hansen, L.A. Cupples, M.P. Reilly, O. Melander, P.M. Mannucci, D. Ardissino, D. Siscovick, R. Elosua, K. Stefansson, C.J. O'Donnell, V. Salomaa, D.J. Rader, L. Peltonen, S.M. Schwartz, D. Altshuler, and S. Kathiresan Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
102. R. Waksman, R. Torguson, K.M. Kent, A.D. Pichard, W.O. Suddath, L.F. Satler, B.D. Martin, T.J. Perlman, J.A. Maltais, N.J. Weissman, P.J. Fitzgerald, and H.B. Brewer Jr. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J. Am. Coll. Cardiol. 55 2010 2727 2735
103. M. Westerterp, C.C. van der Hoogt, W. de Haan, E.H. Offerman, G.M. Dallinga-Thie, J.W. Jukema, L.M. Havekes, and P.C. Rensen Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice Arterioscler. Thromb. Vasc. Biol. 26 2006 2552 2559
104. WHO Study Investigators A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators Br. Heart J. 40 1978 1069 1118
105. J.P. Wilding PPAR agonists for the treatment of cardiovascular disease in patients with diabetes Diabetes Obes. Metab. 14 2012 973 982
106. S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H.M. Princen, and T. Kooistra Mouse models for atherosclerosis and pharmaceutical modifiers Arterioscler. Thromb. Vasc. Biol. 27 2007 1706 1721